NYSEAMERICAN:IBIOIbio Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ibio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ibio.

Ibio is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Ibio.

Ibio's stock reverse split on the morning of Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split.

1 brokers have issued 1-year target prices for Ibio's stock. Their forecasts range from $2.55 to $2.55. On average, they anticipate Ibio's share price to reach $2.55 in the next twelve months. This suggests a possible upside of 30.1% from the stock's current price. View analysts' price targets for Ibio.

News stories about IBIO stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ibio earned a news impact score of -2.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term. View the latest news about Ibio.

Some companies that are related to Ibio include Silence Therapeutics (SLN), Neptune Wellness Solutions (NEPT), TELIX Pharmaceutical (TLX), Starpharma (SPL), ProMetic Life Sciences (PLI), Pfenex (PFNX), IMV (IMV), Emblem (EMC), Medicenna Therapeutics (MDNA), Ergomed (ERGO), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Exicure (XCUR), OncoCyte (OCX) and Theratechnologies (TH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ibio investors own include Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Novavax (NVAX), Nokia Oyj (NOK), Biocept (BIOC), FuelCell Energy (FCEL) and Gilead Sciences (GILD).

Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IBIO stock can currently be purchased for approximately $1.96.

Ibio has a market capitalization of $231.99 million. Ibio employs 54 workers across the globe.

The official website for Ibio is www.ibioinc.com.

Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.